| Literature DB >> 27175061 |
Kerry Wilbur1, Maha Al-Okka1, Ebaa Jumaat1, Nesma Eissa1, Merwa Elbashir1, Sumaya M Al Saadi Al-Yafei2.
Abstract
PURPOSE: Cancer treatments are frequently associated with adverse effects, but there may be a cultural reluctance by care providers to be forthcoming with patients regarding these risks for fear of promoting nonadherence. Conversely, research in a number of countries indicates high levels of patient desire for this information. We sought to explore cancer patient experiences, satisfaction, and preferences for medication risk communication in a Middle East care setting.Entities:
Keywords: Middle East; cancer treatment; risk communication
Year: 2016 PMID: 27175061 PMCID: PMC4854243 DOI: 10.2147/PPA.S99718
Source DB: PubMed Journal: Patient Prefer Adherence ISSN: 1177-889X Impact factor: 2.711
Classification of items significantly allocated to each construct
| Construct (number of items) | Item allocation
| ||
|---|---|---|---|
| Preference | Experience | Satisfaction | |
| Preference (7) | 7 | 0 | 0 |
| Experience (4) | 0 | 4 | 0 |
| Satisfaction (3) | 0 | 0 | 2 |
Demographics of participants
| Characteristic | N=145 | % |
|---|---|---|
| Sex, female | 102 | 70.3 |
| Age, years (mean ± SD) | 46.6 | 12.4 |
| Country of origin | ||
| Qatar | 15 | 10.3 |
| Other GCC | 9 | 6.2 |
| Other Middle East | 43 | 29.7 |
| North Africa | 15 | 10.3 |
| Philippines | 33 | 22.8 |
| Other Southeast Asia | 25 | 17.2 |
| Other | 5 | 3.4 |
| Residing in Qatar, years (mean ± SD) | 13.6 | 13.1 |
| Highest education | ||
| None | 6 | 4.1 |
| Primary school | 14 | 9.7 |
| High school | 26 | 17.9 |
| Diploma | 19 | 13.1 |
| University | 75 | 51.7 |
| First visit to NCCCR | 14 | 9.7 |
| Duration of care at NCCCR, months (mean ± SD) | 13.4 | 19.7 |
| Routes of therapy at NCCCR | ||
| Oral only | 3 | 2.1 |
| Parenteral only | 92 | 63.4 |
| Oral and parenteral administration | 50 | 34.5 |
| Care setting at NCCCR | ||
| Inpatient | 2 | 1.4 |
| Outpatient | 4 | 2.8 |
| Day care | 139 | 95.8 |
Notes: GCC includes Bahrain, Kuwait, Qatar, Saudi Arabia, UAE, and Yemen;
n=140.
Abbreviations: GCC, Gulf Coast Corporation; NCCR, National Center for Cancer Care and Research; SD, standard deviation.
Figure 1Reported recall of actual sources of safety information and expressed preferences.
Notes: Family/friends or the Internet was not option for the first question related to recall of actual sources of safety information. Solicited preferences for safety information sources were not distinguished between type of nurse and type of pharmacist, and so the same value is reported.
Patients expressed preference for medication safety information according to the region of origin
| GCC (n=24) | MENA (n=55) | Philippines (n=33) | Other SE Asia (n=25) | Other (n=5) | |
|---|---|---|---|---|---|
| All or most of the details | 20 (83.3) | 47 (85.5) | 30 (90.9) | 18 (72.0) | 4 (80.0) |
| Not very much or just what I ask | 4 (16.7) | 6 (10.9) | 2 (6.1) | 6 (24.0) | 1 (20.0) |
| Nothing at all | 0 (0) | 2 (3.6) | 1 (3.0) | 1 (4.0) | 0 (0) |
Notes: No statistically significant differences found between GCC and other regions of origin. GCC includes Bahrain, Kuwait, Qatar, Saudi Arabia, UAE, and Yemen.
n=3 did not respond to this question. Data presented as number (%).
Abbreviations: GCC, Gulf Coast Corporation; MENA, Middle East and North Africa; SE, Southeast.
Figure 2Patient level of agreement that knowledge of possible treatment side effects would promote nonadherence according to the region of origin.
Notes: GCC includes Bahrain, Kuwait, Qatar, Saudi Arabia, UAE, and Yemen. *Level of agreement statistically significantly different between GCC and MENA (P-value =0.029) and between GCC and Philippines (P-value =0.030).
Abbreviations: GCC, Gulf Coast Corporation; MENA, Middle East and North Africa; SE, Southeast.